Breckenridge Pharmaceutical Inc. – Trademark Portfolio
Entity Type: 03
Breckenridge Pharmaceutical Inc. holds 78 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 78 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 12 trademarks are registered. Notable registered marks include FOLBEE, FOLBIC, FOLPLEX, FOLTANX, and MULTIGEN. The owner is based in Boca Raton, FL.
P.O. Box 206
Boca Raton, FL 33429
Showing of trademarks Trademarks
Trademark Classifications
Breckenridge Pharmaceutical Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Breckenridge Pharmaceutical Inc. have?
Breckenridge Pharmaceutical Inc. has 78 U.S. trademarks filed with the USPTO. Of these, 12 registered, 40 abandoned, 26 cancelled.
What trademark classes does Breckenridge Pharmaceutical Inc. file in?
Breckenridge Pharmaceutical Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Breckenridge Pharmaceutical Inc.'s most well-known trademarks?
Breckenridge Pharmaceutical Inc.'s registered trademark portfolio includes well-known marks such as FOLBEE, FOLBIC, FOLPLEX, FOLTANX, and MULTIGEN. These are among 12 currently registered trademarks in the portfolio.
What is Breckenridge Pharmaceutical Inc.'s trademark registration success rate?
Breckenridge Pharmaceutical Inc. has a 15% trademark registration rate, with 12 out of 78 resolved applications resulting in successful registration. Currently, 0 applications are pending review.